ArticleFrontiers in cellular and infection microbiology2025
Bone and joint tuberculosis: clinical manifestation, diagnostic techniques and drug resistance analysis.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ischial tuberculosis: MRI and mNGS enable early diagnosis in the largest reported case series of twenty two patients.International orthopaedics · 2026Article
- Primary Tuberculous Osteomyelitis of the Proximal Tibia Presenting as Chronic Osteomyelitis: A Diagnostic Challenge in Musculoskeletal Tuberculosis.Journal of orthopaedic case reports · 2026Article
- miR-29a-3p targets the PI3K/Akt signaling pathway to suppress inflammation and MMP-9-dependent matrix degradation in spinal tuberculosis.Journal of orthopaedic surgery and research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Clinical data on bone and joint tuberculosis (BJTB) in developing countries remain limited. This study aims to investigate the clinical, epidemiological, and drug-resistance characteristics of BJTB patients in Central China and to optimize diagnostic strategies. Methods: This retrospective study analyzed data from patients diagnosed with BJTB at Henan Provincial Chest Hospital between 2016 and 2022. Results: Among the 902 patients, 518 (57.4%) were male and 384 (42.6%) were female. The age groups of 21-30 years and 51-60 years, as well as the rural population, showed the highest prevalence of cases. Local pain was the most prevalent symptom, followed by fever, night sweats, and neurological dysfunction. On average, the time from symptom onset to diagnosis was 6.1 months, and the mean hospital stay was 64.2 days. Spinal tuberculosis was the most frequently affected site, accounting for 77.6% (700/902) of cases. Five diagnostic techniques were evaluated, with GeneXpert MTB/RIF demonstrating superior performance by achieving a sensitivity of 91.6% (95%CI: 86.3%-95.0%) and specificity of 90.1% (95%CI: 85.5%-93.6%). Unlike drug resistance patterns observed in other regions, streptomycin (29.6%) and rifabutin (18.2%) were the most frequently encountered first-line and second-line anti-tuberculosis drugs, respectively. The prevalence of multidrug-resistant tuberculosis (MDR-TB) was 8.3% (95% CI: 5.1%-13.2%), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 1.6% (95% CI: 0.2%-5.6%) of cases. Conclusions: The application of GeneXpert MTB/RIF demonstrated significant diagnostic accuracy for BJTB. The control of MDR-TB remains a critical challenge in the management of BJTB in Central China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.